araag2/HINT huggingface dataset:
Clinical trial NCT00515866 (phase 1, status: completed)
Conditions: pancreatic neoplasms
ICD codes: C25.3
Drugs: ku-0059436 (azd2281)(parp inhibitor), gemcitabine
SMILES: OC1=NN=C(CC2=CC(C(=O)N3CCN(CC3)C(=O)C3CC3)=C(F)C=C2)C2=CC=CC=C12, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically or cytologically confirmed adenocarcinoma of pancreas

          -  Locally advanced or metastatic unresectable disease

        Exclusion Criteria:

          -  No prior anti cancer chemotherapy, radiotherapy (except palliative >4 weeks prior to
             entry, endocrine or immunotherapy or use of other investigational agents;
Clinical trial NCT00246012 (phase 1/phase 2, status: completed)
Conditions: melanoma
ICD codes: C43.0, C43.31, D03.9, C43.51, C43.9, D03.0, C43.4
Drugs: intetumumab, dacarbazine, placebo
SMILES: N1C=CN=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically confirmed melanoma including ocular and mucosal

          -  Documented AJCC (American Joint Committee on Cancer) Stage 3 unresectable or Stage 4
             melanoma (Phase 1); AJCC Stage 4 melanoma (Phase 2)

          -  Radiographically measurable disease or measurable skin lesions

          -  Prior chemotherapy for metastatic melanoma will be allowed for Phase 1, while
             previously untreated for melanoma by chemotherapy will be allowed for Phase 2

          -  Agrees to protocol-defined use of effective contraception

        Exclusion Criteria:

          -  History of receiving murine or human/murine recombination products of human αν
             integrins

          -  Known human immunodeficiency virus (HIV) positivity and clinically important active
             infection

          -  Presence of bone metastases or malignant effusions (non-measurable lesions) and
             central nervous system metastases

          -  Prior radiation to target lesions

          -  Concurrent immunotherapy, biotherapy, radiotherapy, chemotherapy, or investigational
             therapy and therapeutic use of anticoagulation
Clinical trial NCT00232479 (phase 2, status: completed)
Conditions: breast cancer
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: trastuzumab, docetaxel and carboplatin in dose dense regimen
SMILES: [H][N]([H])([H])[Pt]1(OC(=O)C2(CCC2)C(=O)O1)[N]([H])([H])[H]
Eligibility criteria:

        Inclusion Criteria:

          -  HER-2 overexpressing breast cancer

          -  Clinical stage 2-3B

          -  Normal ejection fraction

        Exclusion Criteria:

          -  Metastatic disease

          -  Low ejection fraction
Clinical trial NCT01107938 (phase 2, status: unknown status)
Conditions: gastroesophageal reflux disease
ICD codes: K21.9, K21.00, K21.01
Drugs: 10 mg ilaprazole, 15 mg ilaprazole, 40 mg esomeprazole
SMILES: COC1=C(C)C(C[S+]([O-])C2=NC3=CC(=CC=C3N2)N2C=CC=C2)=NC=C1, COC1=C(C)C(C[S+]([O-])C2=NC3=CC(=CC=C3N2)N2C=CC=C2)=NC=C1, COC1=CC2=C(NC(=N2)[S@@](=O)CC2=NC=C(C)C(OC)=C2C)C=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Consenting patients will be eligible for enrollment if they:

               -  are 18-70 years of age,

               -  have at least one of the two symptoms, heartburn and reflux,

               -  have photographically documented erosive esophagitis confirmed by
                  esophagogastroduodenoscopy(EGD), and graded according to the Los Angeles (LA)
                  Classification (A-D), within 5 days before randomization to treatment. Female
                  patients are required to be nonpregnant, nonlactating, postmenopausal, surgically
                  sterilized, or using a medically acceptable form of birth control, as determined
                  by the investigator. Women of child- bearing potential will receive a pregnancy
                  test.

        Exclusion Criteria:

          -  Patients will be ineligible if they:

               -  have cancerous or peptic ulcers, Zollinger-Ellison syndrome, varices of esophagus
                  or fundus of stomach

               -  have a known history of gastric acid suppression operation, esophageal operation
                  or peptic operation other than simple closure of perforation,

               -  have severe complications, severe other diseases of digestive tract such as
                  Crohn's disease and ulcerative colitis, and severe other systemic diseases,

               -  have taken proton pump inhibitors within the 5 days or for more than three
                  consecutive days within the two weeks immediately preceding start of study drug,

               -  participated in a clinical trial with an investigational drug or device within
                  the past three months,

               -  have hypersensitivity or idiosyncratic reaction to ilaprazole, esomeprazole or
                  any other benzimidazole,

               -  have alcoholic intemperance, drug addiction or any other improper habits.
Clinical trial NCT00310076 (phase 2, status: completed)
Conditions: carcinoma of the appendix, colorectal cancer
ICD codes: C22.0, C22.1, C4A.9, C7B.1, D09.9, C4A.0, C4A.31, C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: thalidomide
SMILES: CC(C)NCC(O)COC1=CC=CC2=C1C=CC=C2
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Pathologically confirmed peritoneal carcinomatosis or adenomucinosis secondary to
             colorectal or appendiceal cancer

               -  Underwent cytoreductive surgery and intraperitoneal hyperthermic chemotherapy
                  (IPHC) within the past 12 weeks

                    -  Patients with residual disease or no evidence of disease after IPHC are
                       eligible

          -  No extra-abdominal disease or parenchymal liver metastases

        PATIENT CHARACTERISTICS:

          -  ECOG performance status 0-3

          -  Free of infection or postoperative complications

          -  Hemoglobin > 8.0 g/dL

          -  Absolute neutrophil count > 1,000/mm³

          -  Platelet count > 100,000/mm³

          -  PTT or PT < 1.5 times normal (except in patients who are receiving therapeutic
             anticoagulant therapy for non-related medical conditions, such as atrial fibrillation)

          -  Bilirubin < 1.5 mg/dL OR direct bilirubin ≤ 1.0 mg/dL (for patients with Gilbert's
             syndrome)

          -  AST/ALT ≤ 2.5 times normal

          -  Serum creatinine < 2.0 mg/dL

          -  No peripheral neuropathy > grade 1, except localized neuropathy due to a mechanical
             cause or trauma

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use 2 effective methods of contraception for 4 months prior to,
             during, and for 4 months after treatment with thalidomide

          -  No history of hepatic cirrhosis

          -  No history of severe hypothyroidism

          -  No history of medical problem such as severe congestive heart failure or active
             ischemic heart disease

          -  No other malignancy within the past 5 years except nonmelanoma skin cancer

          -  No known history of deep vein thrombosis or pulmonary embolus

        PRIOR CONCURRENT THERAPY:

          -  More than 4 weeks since prior chemotherapy, biologic therapy, or radiotherapy (except
             for IPHC)

          -  No other concurrent systemic therapy

          -  No concurrent high level sedatives

          -  No concurrent sedating "recreational" drugs or alcohol
Clinical trial NCT01576380 (phase 2, status: completed)
Conditions: adenocarcinoma, scirrhous, linitis plastica, stomach neoplasms, stomach diseases, neoplasms by site, neoplasms
ICD codes: D13.1, C16.9, C16.1, C16.2, D37.1, C16.8, C16.5, C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2, C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: tki258
SMILES: CN1CCN(CC1)C1=CC=C2N=C(NC2=C1)C1=C(N)C2=C(NC1=O)C=CC=C2F
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosis of advanced/metastatic scirrhous gastric carcinoma

          -  Evidence of diffusely infiltrating gastric lesions and/or at least one measurable
             extra-gastric lesion

          -  Patients previously treated with one or two systemic lines

          -  Documented radiological confirmation of disease progression

          -  ECOG performance status of 0 to 2

          -  Male and female patients aged 20 years or greater

          -  Adequate liver, renal, and hematologic function

        Exclusion Criteria:

          -  Patients who received prior treatment with an FGFR inhibitor

          -  Patients with known brain metastases or who have signs/symptoms attributable to brain
             metastases and have not been assessed with radiologic imaging to rule out the presence
             of brain metastases

          -  Patients with another primary malignancy within 3 years prior to starting study
             treatment

        Other protocol-defined inclusion/exclusion criteria may apply
Clinical trial NCT00640146 (phase 2, status: completed)
Conditions: opioid-induced constipation
ICD codes: F11.14, F11.181, F11.182, F11.188, F11.19, F11.24, F11.281
Drugs: methylnaltrexone bromide, placebo
SMILES: C[N@+]1(CC2CC2)CC[C@]23[C@H]4OC5=C(O)C=CC(C[C@@H]1[C@]2(O)CCC4=O)=C35, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          1. Male and female participants greater than or equal to (>=) 18 years of age.

          2. Participants must have undergone an orthopedic procedure (that is, total knee or hip
             replacement, spinal fusion, or reduction of fracture(s) with or without surgical
             fixation post trauma).

          3. Participants must be receiving opioid analgesics (a mu agonist only-not to include
             agents with mixed mechanisms of action such as tramadol or buprenorphine) after the
             procedures and be expected to require daily opioid analgesics for at least 7 days post
             randomization.

          4. Participants must be acutely constipated following their orthopedic procedure.

          5. Participants must receive all doses of study drug in either hospitals or
             rehabilitation facilities.

          6. Participants must sign an informed consent form.

          7. Females of childbearing potential must have a negative pregnancy test and use
             appropriate birth control throughout the study.

          8. Body weight within range of 40 kilograms (kg) - 150 kg (88 - 330 pounds [lbs]).

        Exclusion Criteria:

          1. Participants with known hypersensitivity to methylnaltrexone, naltrexone, or naloxone.

          2. Participants who received any investigational new drug (experimental) in the previous
             30 days.

          3. Participants who have received a laxative (for example, lactulose) or an enema within
             48 hours prior to the first dose.

          4. Participants with constipation not attributed to post procedure opioids.

          5. Participants with a history of alcohol or prescription or non-prescription drug abuse
             within the past 2 years.

          6. Female participants who are pregnant or lactating.

          7. Participants with a known history of chronic active hepatitis B or hepatitis C virus
             or human immunodeficiency virus (HIV) infection.
Clinical trial NCT00350207 (phase 2, status: completed)
Conditions: asthma
ICD codes: J45.998, J82.83, J45.909, J45.991, J45.20, J45.30, J45.40
Drugs: tiotropium bromide, placebo, salmeterol xinafoate
SMILES: [H][C@]12O[C@@]1([H])[C@]1([H])C[C@@]([H])(C[C@@]2([H])[N+]1(C)C)OC(=O)C(O)(C1=CC=CS1)C1=CC=CS1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, OCC1=C(O)C=CC(=C1)C(O)CNCCCCCCOCCCCC1=CC=CC=C1
Eligibility criteria:

        Inclusion_Criteria:

          1. Patients homozygous for arginine at the 16th amino acid position of the beta2
             adrenergic receptor (B16 Arg/Arg)

          2. All patients must sign and date an Informed Consent Form for the study prior to
             participation in the trial

          3. Male or female outpatients with at least 18 years of age, but not older than 65 years

          4. Patients must have a documented history of asthma

          5. Patients must be current non-smokers or ex-smokers with a cigarette smoking history of
             <10 pack-years

          6. Patients must be on a maintenance treatment with inhaled corticosteroids with a total
             daily dose of 400 - 1000 mcg budesonide or equivalent

        Exclusion_Criteria:

          1. Patients with a significant disease other than asthma

          2. Patients with a recent history (i.e., six months or less) of myocardial infarction

          3. Patients who have been hospitalized for heart failure (New York Heart Association
             class III or IV) within the past year

          4. Patients with any unstable or life threatening cardiac arrhythmia or cardiac
             arrhythmia requiring intervention or a change in drug therapy within the past year

          5. Patients with malignancy for which the patient has undergone resection, radiation
             therapy or chemotherapy within the last five years. Patients with treated basal cell
             carcinoma are allowed.

          6. Patients with a diagnosis of chronic obstructive pulmonary disease (COPD)

          7. Patients with a history of life threatening pulmonary obstruction, or a history of
             cystic fibrosis or clinically evident bronchiectasis

          8. Patients with known active tuberculosis

          9. Patients who have undergone thoracotomy with pulmonary resection.

         10. Patients who have completed a pulmonary rehabilitation program in the six weeks prior
             to visit 1 or patients who are currently in a pulmonary rehabilitation program that
             will not be maintained throughout the duration of the study.
Clinical trial NCT00351715 (phase 2, status: terminated)
Conditions: cancer, pain
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2, N50.82, R07.2, R07.82, R10.13, R10.33, R14.1, R52
Drugs: sublingual methadone
SMILES: CCC(=O)C(CC(C)N(C)C)(C1=CC=CC=C1)C1=CC=CC=C1
Reason stopped: 
    study stopped due to low accrual
  
Eligibility criteria:

        Inclusion Criteria:

          -  Pain due to cancer or its treatment; controlled baseline pain;

          -  episodes of breakthrough pain every day that are "4/10" in severity or greater, ;

          -  ast 10 minutes or longer, and

          -  are responsive to short acting oral opioids such as morphine or hydromorphone;

          -  are able to hole a volume of 1.0cc of water under the tongue for a 5-minute period;
             are able to provide written informed consent;

          -  are able to fill out the study forms

        Exclusion Criteria:

          -  Severe underlying respiratory disease such that an investigator is wary about the risk
             of respiratory failure from modest doses of opioid;

          -  prior sensitivity to methadone;

          -  currently are being administered methadone;

          -  have breakthrough pain that in the opinion of the investigator is likely to change
             within the next seven days (recent or imminent radiation therapy to the main site of
             pain,

          -  new chemotherapy or use of an injectable bisphosphonate likely to alter the pain, new
             use corticosteroids within the past week with a corresponding change in pain, or other
             interventions judged likely to alter pain);

          -  are clinically unstable or have a life expectancy of less than one month making
             completion of the trial unlikely
Clinical trial NCT00467077 (phase 2, status: terminated)
Conditions: kidney cancer
ICD codes: D17.71, D30.00, D30.01, D30.02, D41.00, D41.01, D41.02
Drugs: gefitinib
SMILES: COC1=C(OCCCN2CCOCC2)C=C2C(NC3=CC(Cl)=C(F)C=C3)=NC=NC2=C1
Reason stopped: 
    protocol was closed due to slow accrual.
  
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Histologically or cytologically confirmed renal cell carcinoma

               -  Metastatic or advanced/unresectable disease

          -  Measurable or nonmeasurable disease as defined by RECIST criteria

          -  No uncontrolled brain metastases

               -  Patients with adequately treated brain metastases who are not taking
                  anticonvulsants and corticosteroids may be eligible

        PATIENT CHARACTERISTICS:

          -  Karnofsky performance status 60-100%

          -  Life expectancy ≥ 12 weeks

          -  WBC ≥ 3,500/mm³

          -  Platelet count ≥ 100,000/mm³

          -  Absolute granulocyte count ≥ 1,500/mm³

          -  Creatinine ≤ 2.0 mg/dL OR creatinine clearance ≥ 50 mL/min

          -  Bilirubin ≤ 1.5 mg/dL

          -  AST ≤ 2 times upper limit of normal (ULN)

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception

          -  No other malignancy within the past 5 years except adequately treated basal cell or
             squamous cell carcinoma of the skin, carcinoma in situ of the cervix, or adequately
             treated stage I or II cancer from which the patient is currently in complete remission

          -  No known severe hypersensitivity to gefitinib or its excipients

          -  No incomplete healing from previous oncologic or other major surgery

          -  No unresolved chronic toxicity > grade 2 from previous anticancer therapy (except
             alopecia and anemia)

          -  No evidence of clinically active interstitial lung disease

               -  Patients with chronic stable radiographic changes who are asymptomatic are
                  eligible

          -  No evidence of severe or uncontrolled systemic disease (e.g., unstable or
             uncompensated respiratory, cardiac, hepatic, or renal disease)

          -  No other significant clinical disorder or laboratory finding that would preclude study
             participation

        PRIOR CONCURRENT THERAPY:

          -  More than 30 days since prior nonapproved or investigational drugs

          -  More than 6 weeks since prior aldesleukin or interferon and recovered

          -  At least 3 weeks since prior radiotherapy

          -  No prior gefitinib

          -  Prior chemotherapy or biological therapy allowed

          -  Prior or concurrent bisphosphonate therapy for bone metastases allowed

          -  No concurrent phenytoin, carbamazepine, rifampin, barbiturates, phenobarbital, or
             Hypericum perforatum (St. John's wort)

          -  No other concurrent agents specifically designed to inhibit the epidermal growth
             factor receptor (EGFR)

          -  No concurrent radiotherapy to measurable lesions
Clinical trial NCT00544362 (phase 1/phase 2, status: completed)
Conditions: esophageal cancer
ICD codes: K22.2, K22.81, Q39.4, P78.83, I85.00, I85.01, I85.10
Drugs: cisplatin, fluorouracil
SMILES: [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Eligibility criteria:

        DISEASE CHARACTERISTICS:

        Inclusion criteria:

          -  Histologically confirmed epidermoid or glandular carcinoma of the thoracic esophagus

               -  Invasive disease

               -  Only Siewert type I gastroesophageal carcinoma allowed

          -  Resectable disease

               -  T1N+, T2N0, T2N+, T3N0, or T3N+ (stage II or III)

               -  No visceral metastases or mediastinal extensions compromising resectability

        Exclusion criteria:

          -  Inoperable disease

          -  Invasion of the tracheo-bronchial tree

          -  Recurring esophageal paralysis

          -  Esopho-tracheal fistula

          -  Cervical esophageal carcinoma (< 19 cm above the dental arches)

          -  Multifocal esophageal carcinoma

          -  Superficial esophageal carcinoma (T1N0)

          -  Esophageal carcinoma in the lymph nodes that cannot be included in the radiotherapy
             field or cannot be completely surgically resected

          -  Proven metastatic disease

        PATIENT CHARACTERISTICS:

        Inclusion criteria:

          -  WHO performance status 0-1

          -  Weight loss < 15%

          -  Absolute neutrophil count ≥ 1,500/mm3

          -  Platelet count ≥ 100,000/mm3

          -  Creatinine ≤ 1.25 times upper limit of normal

          -  PTT ≥ 80%

          -  Albumin ≥ 35 g/L

          -  FEV1 > 1 L

          -  Not pregnant or nursing

          -  Fertile patients of must use effective contraception

        Exclusion criteria:

          -  Known liver cirrhosis

          -  Renal insufficiency

          -  Respiratory insufficiency (i.e., severe dyspnea at rest or oxygen dependence)

          -  Progressive coronary insufficiency

          -  Myocardial infarction in the past 6 months

          -  Legally incapacitated

          -  Impossible to receive study therapy due to geographical, social, or psychological
             reasons

          -  Noncompliant within constraints of the study

          -  Hematologic malignancy or other cancer except carcinoma in situ of the uterine cervix,
             treated nonmelanoma skin cancer, or intramucous disease treated within the past 3
             years

        PRIOR CONCURRENT THERAPY:

        Exclusion criteria:

          -  Prior anticancer chemotherapy or radiotherapy

          -  Treatment with endoprosthesis

          -  Surgery (esophagectomy) planned without thoracotomy
Clinical trial NCT00109135 (phase 2, status: completed)
Conditions: smoking
ICD codes: O99.334, O99.335, Y93.G2, O99.330, O99.331, O99.332, O99.333
Drugs: taranabant
SMILES: C[C@H](NC(=O)C(C)(C)OC1=CC=C(C=N1)C(F)(F)F)[C@@H](CC1=CC=C(Cl)C=C1)C1=CC=CC(=C1)C#N
Eligibility criteria:

        Inclusion Criteria:

          -  Smoking greater than/equal to 10 cigarettes/day for at least 1 year

          -  Laboratory tests that meet the criteria of the study

          -  In overall good health as determined by the investigator

        Exclusion Criteria:

          -  Psychiatric diagnoses

          -  Certain cancers

          -  Patients who use nicotine replacement therapy

          -  Patients on a diet regimen
Clinical trial NCT01809262 (phase 2, status: completed)
Conditions: pulmonary disease, chronic obstructive
ICD codes: J44.9, J44.1, J44.0
Drugs: single dose of 5 mcg, single dose of placebo, single dose of 40 mcg, single dose of 20 mcg, single dose of 2 mcg, single dose of 10 mcg
SMILES: COC1=CC=C(CC(C)(C)NC[C@H](O)C2=C3OCC(=O)NC3=CC(O)=C2)C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, COC1=CC=C(CC(C)(C)NC[C@H](O)C2=C3OCC(=O)NC3=CC(O)=C2)C=C1, COC1=CC=C(CC(C)(C)NC[C@H](O)C2=C3OCC(=O)NC3=CC(O)=C2)C=C1, COC1=CC=C(CC(C)(C)NC[C@H](O)C2=C3OCC(=O)NC3=CC(O)=C2)C=C1, COC1=CC=C(CC(C)(C)NC[C@H](O)C2=C3OCC(=O)NC3=CC(O)=C2)C=C1
Eligibility criteria:

        Inclusion criteria:

          1. Diagnosis of chronic obstructive pulmonary disease

          2. Smoking history of more than 10-pack years

        Exclusion criteria:

          1. History of asthma, allergic rhinitis, myocardial infarction or unstable of
             life-threatening cardiac arrhythmias

          2. Marked baseline prolongation of QT/QTc interval